He noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...

Q-Gold Resources Ltd (TSXV: QGR, OTC: QGLDF) ("Q-Gold" or the "Company") is pleased to announce that the Company intends to use a portion of the proceeds ...

Q-Gold Resources Ltd (TSXV: QGR, OTC: QGLDF) (“ Q-Gold ” or the “ Company ”) is pleased to announce that the Company intends to use a portion of the proceeds of its recently completed oversubscribed ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

There are many symptoms that are common to a wide variety of diseases, like fever, which can indicate an infection, autoimmune disease, or ... | Clinical And Molecular Dx ...

Profiling cells from ovarian endometriosis revealed signaling interactions that may sustain legion growth, highlighting ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

The effort by the Emerging & Pandemic Infections Consortium (EPIC), one of several U of T institutional strategic initiatives ...